Danish biotech company 7TM Pharma has announced in a press release the signing of a drug discovery collaboration with India's Dr. Reddy’s Laboratories on selected drug targets in the area of metabolic disorders.
The two companies will jointly develop candidate drugs up to proof-of-concept stage (Phase IIa). If this stage is reached successfully, the companies may either license-out the candidates to larger pharmaceutical companies for further development or continue co-development and commercialization themselves. The financial terms of the agreement were not disclosed.
Mette Kirstine Agger, CEO of 7TM Pharma, says in the press release: “It is exciting to be working with Dr. Reddy’s, as they have developed strong R&D capabilities and combining this with 7TM's expertise in the GPCR* area and SD3 [7TM’s technology platform] we are looking forward to a fruitful collaboration.”
Dr. Rajinder Kumar, R&D chief at Dr. Reddy’s, comments: “7TM has established a track record as one of the leading drug discovery companies focusing on GPCRs, and we are excited at the prospects of combining 7TM’s capabilities with Dr. Reddy’s to discover and develop innovative products.”
7TM Pharma is a biotech company focusing on discovery and development of new drugs targeting 7TM receptors. 7TM Pharma’s primary therapeutic area is metabolic diseases, including obesity, type 2 diabetes and cardiovascular diseases. The basis for 7TM Pharma’s drug discovery is its comprehensive knowledge of 7TM receptors, which the company uses in the design of new potential drugs.
* G protein-coupled receptors, also known as 7TM receptors, are cell membrane receptors that sense molecules outside the cell and activate intra-cellular responses - Ed.